Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of non-incretin products, which grew sales 20% in the fourth quarter, should “help ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Eli Lilly's sales growth is coming short of expectations, which is a problem considering its valuation. The company does have a vast lineup and a deep pipeline that go beyond diabetes and obesity.

Eli Lilly's operational performance is strong, but shares are expensive, leading me to reaffirm a 'hold' rating despite potential upside from new drugs. Recent financial results show significant ...

Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly LLY and Novo Nordisk NVO stock. As the major players in the hyper-scale ...

Eli Lilly & Co.’s fourth-quarter revenue fell short of analysts’ estimates as the drugmaker struggled to forecast demand for its popular weight-loss and diabetes shots for the second quarter ...

Lilly now expects fourth-quarter sales of $3.5 billion for diabetes drug Mounjaro and $1.9 billion for Zepbound. That is much higher than a year earlier but Explore Our Brands ...